Early registration rates end this coming Monday for #mDNASRC. Join your colleagues in beautiful Porto alongside organizers like @bengrbm.bsky.social. Save your space: buff.ly/P6hZjQz

MSK is pleased to announce @time.com has named two MSK physician-scientists, Dr. Andrea Cercek and Dr. Vinod Balachandran, to the 2025 TIME100 Health, a list of the most influential individuals in health and medicine who have made significant contributions to industry. Learn more: bit.ly/3GGblTR

Call for abstracts! #mDNASRC is in beautiful Porto this year! Organizers @bengrbm.bsky.social, John LaCava, Zhao Zhang, and Vera Gorbunova may select you for a poster session or short talk. You can even register now and submit your abstract later. Save your space: buff.ly/PAKp55o

Come out tomorrow at 10 am to learn about transposable elements in cancer - it will be a great session with @chiappinellilab.bsky.social & Ting Wang #AACR25! @theaacr.bsky.social

Great article in @science.org highlighting our efforts to target the #darkproteome! Nice to see our colleagues David Ting, Daniel De Carvalho, and Marty Taylor highlighted along with the amazing work of @rometx.bsky.social👇👇👇 www.science.org/content/arti...

#mDNASRC is back and stronger than ever after 30 years! Discover how transposable elements shape our genomes and impact health, featuring keynote speaker @bengrbm.bsky.social, and more! Save your space: buff.ly/QiSc4E6

Thank you @mskcancercenter.bsky.social for highlighting our work and our great collaborators!

Our latest work on the #darkgenome is out now in @naturecomms.bsky.social. LINE-1 is the only known autonomous retrotransposon still active in our genome. Co-led by our Alexander Solovyov @MSKCancerCenter - our work was also great collaboration with @rome_tx 👇👇👇 nature.com/articles/s4146

We’re excited to announce a new publication in Nature Communications: the first large-scale, pan-cancer analysis of LINE-1 expression levels and retrotransposition (RT) activity. These data demonstrate the potential for precision LINE-1 RT-targeted therapeutic approaches. rometx.com/press-releas...

An new publication in @Nature by SU2C Convergence Team leaders @thevinodlab.bsky.social @bengrbm.bsky.social @mskcancercenter.bsky.social showed an individualized neoantigen mRNA vaccine for #pancreaticcancer led to prolonged survival and effector T cell responses www.nature.com/articles/s41...

(1/2) Results from a phase 1 clinical trial of the #mRNA-based therapeutic cancer vaccine autogene cevumeran for treating #pancreaticcancer is published in @nature.com. bit.ly/4b9ofEZ

A new study in @cellpress.bsky.social Immunity from the lab of Dr. Benjamin Greenbaum provides insights into how #PancreaticCancer cells accommodate active retrotransposons without triggering the innate immune response. #oncsky #medsky